Oracle Alpha Inc. Nurix Therapeutics, Inc. Transaction History
Oracle Alpha Inc.
- $55.7 Billion
- Q1 2024
A detailed history of Oracle Alpha Inc. transactions in Nurix Therapeutics, Inc. stock. As of the latest transaction made, Oracle Alpha Inc. holds 11,538 shares of NRIX stock, worth $229,952. This represents 0.3% of its overall portfolio holdings.
Number of Shares
11,538
Previous 17,434
33.82%
Holding current value
$229,952
Previous $180 Million
5.73%
% of portfolio
0.3%
Previous 0.23%
Shares
2 transactions
Others Institutions Holding NRIX
# of Institutions
181Shares Held
68.1MCall Options Held
78KPut Options Held
53.8K-
Black Rock Inc. New York, NY6.82MShares$136 Million0.0% of portfolio
-
Redmile Group, LLC San Francisco, CA4.28MShares$85.3 Million6.28% of portfolio
-
Vanguard Group Inc Valley Forge, PA4.01MShares$80 Million0.0% of portfolio
-
Baker Bros. Advisors LP New York, NY3.88MShares$77.4 Million0.93% of portfolio
-
Deep Track Capital, LP Greenwich, CT3.87MShares$77.1 Million3.2% of portfolio
About Nurix Therapeutics, Inc.
- Ticker NRIX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 47,147,800
- Market Cap $940M
- Description
- Nurix Therapeutics, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of small molecule therapies for the treatment of cancer and immune disorders. The company develops NX-2127, an orally available Bruton's tyrosine kinase (BTK) degrader for the treatment of relapsed or refractory B-cell malignancies...